Deleted in liver cancer-1 (DLC1): An emerging metastasis suppressor gene

Nicholas C. Popescu, Steven Goodison

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

While significant progress continues to be made in the early detection and therapeutic management of primary tumors, the incidence of metastatic disease remains the major cause of mortality. Accordingly, the development of novel effective therapies that can ameliorate dissemination and secondary tumor growth are a clinical priority. The identification of genetic and functional alterations in cancer cells that affect factors implicated in the metastatic process is critical for designing preventive and therapeutic strategies. Evidence implicating the protein deleted in liver cancer-1 (DLC1), a Rho GTPase activator, in metastasis has accumulated to a point where DLC1 may be considered as a metastasis suppressor gene. This review presents evidence supporting an anti-metastatic role for DLC1 in several human cancers and discusses the mechanisms contributing to its inhibitory effects. In addition, promising opportunities for therapeutic interventions based on DLC1 function and downstream pathways involved in the metastatic process are considered.

Original languageEnglish (US)
Pages (from-to)293-302
Number of pages10
JournalMolecular Diagnosis and Therapy
Volume18
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Liver Neoplasms
Tumor Suppressor Genes
GTP Phosphohydrolase Activators
Neoplasms
rho GTP-Binding Proteins
Therapeutics
Neoplasm Metastasis
Mortality
Incidence
Growth
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Deleted in liver cancer-1 (DLC1) : An emerging metastasis suppressor gene. / Popescu, Nicholas C.; Goodison, Steven.

In: Molecular Diagnosis and Therapy, Vol. 18, No. 3, 01.01.2014, p. 293-302.

Research output: Contribution to journalReview article

@article{f69688096a274fbf9f72209ff3601b75,
title = "Deleted in liver cancer-1 (DLC1): An emerging metastasis suppressor gene",
abstract = "While significant progress continues to be made in the early detection and therapeutic management of primary tumors, the incidence of metastatic disease remains the major cause of mortality. Accordingly, the development of novel effective therapies that can ameliorate dissemination and secondary tumor growth are a clinical priority. The identification of genetic and functional alterations in cancer cells that affect factors implicated in the metastatic process is critical for designing preventive and therapeutic strategies. Evidence implicating the protein deleted in liver cancer-1 (DLC1), a Rho GTPase activator, in metastasis has accumulated to a point where DLC1 may be considered as a metastasis suppressor gene. This review presents evidence supporting an anti-metastatic role for DLC1 in several human cancers and discusses the mechanisms contributing to its inhibitory effects. In addition, promising opportunities for therapeutic interventions based on DLC1 function and downstream pathways involved in the metastatic process are considered.",
author = "Popescu, {Nicholas C.} and Steven Goodison",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s40291-014-0086-3",
language = "English (US)",
volume = "18",
pages = "293--302",
journal = "Molecular Diagnosis and Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Deleted in liver cancer-1 (DLC1)

T2 - An emerging metastasis suppressor gene

AU - Popescu, Nicholas C.

AU - Goodison, Steven

PY - 2014/1/1

Y1 - 2014/1/1

N2 - While significant progress continues to be made in the early detection and therapeutic management of primary tumors, the incidence of metastatic disease remains the major cause of mortality. Accordingly, the development of novel effective therapies that can ameliorate dissemination and secondary tumor growth are a clinical priority. The identification of genetic and functional alterations in cancer cells that affect factors implicated in the metastatic process is critical for designing preventive and therapeutic strategies. Evidence implicating the protein deleted in liver cancer-1 (DLC1), a Rho GTPase activator, in metastasis has accumulated to a point where DLC1 may be considered as a metastasis suppressor gene. This review presents evidence supporting an anti-metastatic role for DLC1 in several human cancers and discusses the mechanisms contributing to its inhibitory effects. In addition, promising opportunities for therapeutic interventions based on DLC1 function and downstream pathways involved in the metastatic process are considered.

AB - While significant progress continues to be made in the early detection and therapeutic management of primary tumors, the incidence of metastatic disease remains the major cause of mortality. Accordingly, the development of novel effective therapies that can ameliorate dissemination and secondary tumor growth are a clinical priority. The identification of genetic and functional alterations in cancer cells that affect factors implicated in the metastatic process is critical for designing preventive and therapeutic strategies. Evidence implicating the protein deleted in liver cancer-1 (DLC1), a Rho GTPase activator, in metastasis has accumulated to a point where DLC1 may be considered as a metastasis suppressor gene. This review presents evidence supporting an anti-metastatic role for DLC1 in several human cancers and discusses the mechanisms contributing to its inhibitory effects. In addition, promising opportunities for therapeutic interventions based on DLC1 function and downstream pathways involved in the metastatic process are considered.

UR - http://www.scopus.com/inward/record.url?scp=84902362250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902362250&partnerID=8YFLogxK

U2 - 10.1007/s40291-014-0086-3

DO - 10.1007/s40291-014-0086-3

M3 - Review article

C2 - 24519699

AN - SCOPUS:84902362250

VL - 18

SP - 293

EP - 302

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1177-1062

IS - 3

ER -